// immunotherapies

eTheRNA
Immunotherapies

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

To fight cancer, eTheRNA adopts multiple strategies including : 

New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.

An innovative mRNA mix that mimics the action of oncolytic viruses to induce immunogenic death of tumor cells and renders the tumor more susceptible towards the anti-tumor T cell response

The different approaches can be combined with each other and other classes of treatment interventions.

To fight infectious diseases, eTheRNA is adapting its proprietary

TriMix technology to a product that can be administered intranasally and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including CoV-19 (coronavirus).

eTheRNA Pipeline Overview

Project Code

Project Name

Indication

Stage

Mode

Administration

Oncology

A001

IN naked mRNA vaccine for melanoma

Metastatic melanoma

Phase I / II

Immuno-stimulation

Loco-regional (intranodal)

A002

LNP based E6E7 vaccine

HNSCC

Preclinical

Immuno-stimulation

Systemic (IV)

A003

IT optimized TriMix

Undisclosed

Lead opt'n

Oncolysis

Loco-regional (IT)

A004

Cell death induction

Undisclosed

Lead opt'n

Oncolysis

Loco-regional (IT)

A005

Frameshifted NeoAgs

RCC

Discovery

Immuno-stimulation

Systemic (IV)

Non-Oncology

A006

NoseVAx

Infectious Disease

Discovery

Immuno-stimulation

Loco-regional (intranasal)

A007

Novel immunotherapy

Undisclosed

Discovery

-

To be determined

Technology

Platform expansion

ID / autoimmune

Discovery

-

Systemic (IV)

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk